NCT01622868: Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

NCT01622868
Breast Cancer Type: HER2++
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Leptomeningeal disease
https://ClinicalTrials.gov/show/NCT01622868

Comments are closed.

Up ↑